SALTO - Epidemiological Study on Compliance and Treatment Satisfaction

Compliance and Treatment Satisfaction in Prophylaxis of Postsurgical Thromboembolism

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00911001

Acronym

SALTO

Enrollment

480

Registered

2009-06-01

Start date

2008-11-30

Completion date

2009-03-31

Last updated

2013-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thromboembolism

Keywords

Arthroplasty, Antithrombotic prophylaxis treatment, Replacement, Knee

Brief summary

Patients that are on total knee/hip replacement initiate prophylaxis treatment on the hospital ground. Once they leave the hospital, as outpatients they continue with the treatment at least during two consecutive weeks. Patients will be instructed to follow treatment recommendations (either LMWH or oral treatment, at physician discretion) and to come back to the surgeon after that period. At that visit, the Treatment Satisfaction Questionaire with Medication (TSQM) test as well as the Moriski-Green Questionaire (measures compliance with medication) will be answer by the patient. TSQM is an self administered validated scale (validated also in spanish) that measures in a generic way the treatment satisfaction to a treatment. Morinski-Green test will be used to measure the compliance degree on medication.

Interventions

BEHAVIORALNo Drug

Patients in daily life clinical treatment receiving pharmacological agents to prevent VTE.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients in antithrombotic prophylaxis treatment after total knee/hip replacement. This is an epidemiological study where the patients to be included will be those that are treated with antithrombotics as out-patients in real life conditions.

Exclusion criteria

* Patients who has been previously treated with injectable antithrombotic treatments. * Diabetic patients treated with insulin. * Patients who do not sign Informed Consent Form.

Design outcomes

Primary

Measure	Time frame
To measure the Treatment Satisfaction with medication through the self administered scale TSQM.	2 weeks

Secondary

Measure	Time frame
To measure compliance with medication and the relationship with satisfaction through the Moriski-Green Questionaire	2 weeks

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026